#Cancer Treatment


Exercise Lying Down? Absolutely!

Right before I was diagnosed with ovarian cancer, I was the fittest I had ever been in my life. I ran almost every day with my golden retriever and played soccer with my husband on a co-ed soccer team (I was terrible, but I blew through 500+ calories with every game). In fact, it was being hit with a soccer ball that sent me to the nurse practitioner who found my spreading cancer.
Picture for Exercise Lying Down? Absolutely!

All in My Head by Jessica Morris review – a candid and defiant memoir about cancer

“I didn’t choose cancer. Cancer chose me.” None of us know what we will do when we’re given the sentence of our death. For Jessica Morris, the sentence came too early, when she was in her early 50s, strong and vigorous, her three children not yet adults, her future seeming to lie clear and unimpeded in front of her. And it came out of the blue: hiking with friends in the Catskills in upstate New York in 2016, she began to feel strangely breathless and “inexplicably odd… odder still… struggling to call out during a nightmare… Agh…” The violent seizure she then had was her body’s “suicide mission” revealing itself.
Picture for All in My Head by Jessica Morris review – a candid and defiant memoir about cancer

New chemical modification of a natural compound for cancer treatment

Natural compounds often have promising therapeutic potential but using them to treat diseases is hampered due to toxicity or non-desirable effects. Now, a new study led by Gonçalo Bernardes, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) and Professor at the University of Cambridge (Cambridge, U.K.), and Gonzalo Jiménez-Osés, group leader at the Center for Cooperative Research in Biosciences (Derio, Spain), and published today in the scientific journal Nature Chemistry reports the development of new chemistry on natural compounds derived from Brazilian lapacho tree bark to obtain a therapeutic agent that could be an efficient treatment for acute myeloid leukemia.
Picture for New chemical modification of a natural compound for cancer treatment

Kavita Jackson, MD

Kavita Jackson, MD, is a triple-negative breast cancer survivor. As a girl mom and woman of color who was diagnosed with breast cancer at age 32, she empowers other women by promoting self-breast exams, dispelling common breast cancer myths, and sharing her raw experience on the other side of medicine. Connect with her on Instagram.

Suh Jung Hee Dead? Korean Actress Speaks Up After Emergence of Death Hoax

Suh Jung Hee spoke up after fake news about her death emerged. Suh Jung Hee has been through worse in her personal life and career in the past years. Most recently, the actress and model revealed that she was diagnosed with breast cancer in April. She has since undergone surgery...

New drugs may help kill bowel cancer

Scientists from the Hudson Institute of Medical Research found drugs that are being tested to treat leukemia could also be used to fight bowel cancer. The research is published in Science Advances and was conducted by Dr. Chunhua Wan et al. In the study, the team used Nobel Prize-winning genetic...

Doctors overestimate success of multi-step medical procedures

Whether a woman is giving birth or a man is having a cancer biopsy, medical care is rarely straightforward. At any point, an unexpected complication can arise, particularly during treatments that require several steps. Yet physicians tend to have unrealistic expectations of the success of multi-step medical procedures, according to...

GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway

Hepatocellular carcinoma (HCC) contributes to a heavy disease burden for its high prevalence and poor prognosis, with limited effective systemic therapies available. In the era of precision medicine, treatment efficacy might be improved by combining personalized systemic therapies. Since oncogenic activation is one of the primary driving forces in HCC, characterization of these oncogenes can provide insights for developing new targeted therapies. Based on RNA sequencing of epithelial-mesenchymal transition (EMT)-induced HCC cells, this study discovers and characterizes glioma pathogenesis-related protein 1 (GLIPR1) that robustly drives HCC progression and can potentially serve as a prognostic biomarker and therapeutic target with clinical utility. GLIPR1 serves opposing roles and involves distinct mechanisms in different cancers. However, based on integrated in-silico analysis, in vitro and in vivo functional investigations, we demonstrate that GLIPR1 plays a multi-faceted oncogenic role in HCC development via enhancing tumor proliferation, metastasis, and 5FU resistance. We also found that GLIPR1 induces EMT and is actively involved in the PI3K/PDK1/ROCK1 singling axis to exert its oncogenic effects. Thus, pre-clinical evaluation of GLIPR1 and its downstream factors in HCC patients might facilitate further discovery of therapeutic targets, as well as improve HCC chemotherapeutic outcomes and prognosis.

Most Doctors Found To Have A Serious Disorder: New Study Alerts

Medical care is rarely straightforward, whether a woman is giving birth or a man is having a cancer biopsy. During multi-step therapies, complications can emerge at any time. However, a recent study by experts from the University of Utah Health and their partners found that physicians frequently have exaggerated expectations about the effectiveness of complicated medical treatments.

Breakthrough in treating cancer that killed The Wanted's Tom Parker? New drug which 'starves tumours could be first to get approval in over 20 years'

A drug which starves cancer cells could be the first breakthrough in brain tumour treatment for two decades, experts hope. Imperial College London scientists conducted tests in mice who had glioblastoma (GBM) — one of the most aggressive forms of brain cancer. They gave rodents an experimental drug which...

Woman who faked cancer treatment to defraud people of £45,000 will pay back just £5

A woman who defrauded people of more than £45,000 by claiming she needed to have private cancer treatment has been ordered to repay £5.Nicole Elkabbas, 44, from Broadstairs in Kent, duped about 700 people into contributing to her crowdfund appeal by telling them she had to have the treatment at a clinic in Spain.Her consultant oncologist had found Elkabbas’ GoFundMe page – seemingly set up by her mum – just days after examining her and giving her the all-clear for ovarian cancer.The crowdfund page posted in 2018, titled ‘Nicole Needs Our Help Treatment’, shows a photo of Elkabbas in a...

Baptist Health Acquires Sophisticated New Platform for Brain Tumor Treatments

Always seeking to further the level of care available to cancer patients in the region, Baptist Health South Florida has added a sophisticated new radiosurgery platform to its arsenal of cancer-fighting technology. The ZAP-X® Gyroscopic Radiosurgery® platform for cranial stereotactic radiosurgery (SRS) will be used by Miami Neuroscience Institute, in collaboration with Miami Cancer Institute, to treat advanced brain tumors, executives of the health system say.

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer

Recombinant human endostatin (Endostar) plus vinorelbine/cisplatin (NP) had been approved for the treatment of non-small cell lung cancers (NSCLC). But the real-world treatment pattern and effectiveness of Endostar plus other combination chemotherapy, namely docetaxel/platinum (DP), gemcitabine/platinum (GP), pemetrexed/platinum (PP), and paclitaxel/platinum (TP) in both treatment-naïve and re-treatment patients with advanced NSCLC were still unclear. A retrospective observational study was conducted based on the electronic medical record (EMR) system and advanced patients with NSCLC were identified from 7 cancer hospitals in China from 2012 to 2019. These patients were divided into five groups, Endostar plus NP, Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP groups. The disease control rate (DCR), overall response rate (ORR), and the progression-free survival (PFS) were evaluated. Of the eligible 512 advanced patients with NSCLC, 10.35% were in Endostar plus NP group, while the numbers were 15.43%, 32.42%, 26.56%, 15.23% in Endostar plus DP group, Endostar plus GP group, Endostar plus PP group, and Endostar plus TP group, respectively. The ORRs were 31%, 28%, 22%, 41% and 27%, and the DCRs were 71%, 72%, 57%, 72% and 76%, respectively. The median of PFSs for the above groups were 7.9, 6.8, 5.6, 13.7, and 5.4 months. Compared with Endostar plus NP group, the hazard ratios (HRs) and 95%CIs of Endostar plus other chemotherapy were 1.86 (0.75"“4.61), 2.15 (0.83"“5.60), 1.33 (0.51"“3.44), and 2.42 (0.86"“6.81). This real-world study found the effectiveness of Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP were of no statistically significant differences compared with Endostar plus NP and reflected the good effectiveness of Endostar plus different chemotherapy in advanced patients with NSCLC.

Sleep and Lung Cancer: What's the Connection?

There is a connection between sleep and lung cancer. As with other types of cancer, side effects of treatments such as chemotherapy can make it difficult for people to fall asleep, stay asleep, return to sleep, or get quality sleep. A good night's sleep is important to not only help...
NBC 29 News

Virginia budget funds new position at UVA Children’s Hospital

CHARLOTTESVILLE, Va. (WVIR) - For the first time, support for children with cancer is being included in Virginia’s budget. The new budget will go into effect July 1. “The funding is going to provide a full-time dedicated educational support navigator for each of the five treatment centers,” Amy Godkin with ASK Childhood Cancer Foundation.

University of Louisville receives $1.5M grant to expand cancer trials

LOUISVILLE, Ky. (WDRB) -- University of Louisville Health's Brown Cancer Center has been granted $1.5 million to expand its clinical trials for cancer immunotherapy. The gift, provided by the The Gibbs Foundation Inc, will fund research staff for three years, and increase capacity for trial participants, according to a news release.